Phathom Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.07, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Average collection period, for Phathom Pharmaceuticals Inc 's accounts receivable remained unchanged at 119 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 154 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1371, from overall ranking in the first quarter 2026 at 3104.

What is Receivable Turnover Ratio?
What is Phathom Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PHAT Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	90.07 %	121.99 %	101.38 %	165.01 %	371.22 %
Y / Y Revenue Change	88.02 %	104.43 %	94.12 %	202.74 %	439.36 %
Receivable Turnover Ratio (TTM)	3.07	3.08	3.16	3.23	3.09
PHAT's Total Ranking	# 1371	# 3104	# 2508	# 1891	# 1917
Accounts Receivable average collection period days	119	118	115	113	118
Seq. Receivable Change	20.69 %	3.32 %	40.04 %	8.85 %	40.95 %
Seq. Revenue Change	27.4 %	1.25 %	16.32 %	25.32 %	38.51 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 40
Healthcare Sector	# 155
Overall Market	# 1371

Receivable Turnover Ratio Statistics
High	Average	Low
0.85	0.45	0.07
(Jun 30 2026)		(Sep 30 2024)

PHAT Company Profile • Back to PHAT Efficiency Comparisons • Compare PHAT Receivables Turnover Ratio to its Competitors

Financial Statements
Phathom Pharmaceuticals Inc 's Accounts Receivable	$ 97 Millions	Visit PHAT's Balance sheet
Phathom Pharmaceuticals Inc 's Sales TTM	$ 240 Millions	Visit PHAT's Income Statement
Sources of PHAT's Revenues		Visit PHAT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PHAT's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PHAT's Growth Rates	PHAT's Roa	PHAT's Inventory Turnover Ratio	PHAT's Dividend Comparisons
PHAT's Profitability Ratios	PHAT's Roi	PHAT's Asset Turnover Ratio	PHAT's Dividend Growth
PHAT's Valuation Ratios	PHAT's Roe	PHAT's Financial Strength Ratios	PHAT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Moderna Inc	6.76	$ 2,228.000 Millions	$ 329.500 Millions
Carlisle Companies Incorporated	6.76	$ 5,097.000 Millions	$ 754.025 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Envista Holdings Corporation	6.69	$ 2,856.400 Millions	$ 427.250 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Ufp Technologies Inc	6.65	$ 632.042 Millions	$ 94.976 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Livanova Plc	6.62	$ 1,470.112 Millions	$ 222.035 Millions
Agilon Health Inc	6.61	$ 5,920.015 Millions	$ 895.120 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Beone Medicines Ltd	6.58	$ 6,128.238 Millions	$ 930.639 Millions
Embecta Corp	6.57	$ 1,019.700 Millions	$ 155.125 Millions
Editas Medicine Inc	6.57	$ 47.005 Millions	$ 7.156 Millions
Labcorp Holdings Inc	6.49	$ 14,348.000 Millions	$ 2,210.975 Millions
Intellia Therapeutics Inc	6.44	$ 59.506 Millions	$ 9.243 Millions
Cvrx inc	6.44	$ 60.164 Millions	$ 9.345 Millions
Schrodinger Inc	6.43	$ 259.035 Millions	$ 40.267 Millions
Baxter International Inc	6.43	$ 11,555.000 Millions	$ 1,798.000 Millions
Healthcare Services Group Inc	6.42	$ 1,864.594 Millions	$ 290.515 Millions
Verastem Inc	6.42	$ 87.526 Millions	$ 13.640 Millions
Haemonetics Corporation	6.42	$ 1,351.722 Millions	$ 210.662 Millions
Macrogenics Inc	6.41	$ 167.674 Millions	$ 26.170 Millions
Bruker Corporation	6.41	$ 3,498.900 Millions	$ 546.100 Millions
Adaptive Biotechnologies Corporation	6.38	$ 308.081 Millions	$ 48.254 Millions
Iradimed Corporation	6.38	$ 86.339 Millions	$ 13.533 Millions
Aquestive Therapeutics Inc	6.37	$ 54.087 Millions	$ 8.489 Millions

Date modified: 2026-09-14T03:59:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.